Merck KGaA

Research and Markets Adds Report: Pipeline Insight: Colorectal Cancer.
Health & Beauty Close-Up; 11/17/2009; 871 words; ...Lilly and Company - Genentech, Inc. - Human Genome Sciences, Inc. - IMS Health - Keryx Biopharmaceuticals, Inc. - Merck KGaA - Schering-Plough Corp. Report information: http://www.researchandmarkets.com/research/476754/pipeline...

Idera Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides Pipeline Update.(Financial report)
Cancer Vaccine Week; 11/16/2009; 1139 words; ...31, 2008. Clinical and Preclinical Programs IMO-2055, a TLR9 agonist, in Cancer Treatment (collaboration with Merck KGaA) Phase 2 Clinical Trial of IMO-2055 in Renal Cell Carcinoma (RCC) In September 2009, the Company presented final...

Particles Detected in Vials from Genzyme's Plant Not Expected to Impact Aldurazyme or Naglazyme.
PR Newswire; 11/13/2009; 1074 words; ...sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine...

The Pharmaceutical Market: Australia.
M2 Presswire; 11/12/2009; 1005 words; ...USA, Italy, Ireland and Germany. The leading local company, Alphapharm, is a generic supplier formerly part of Merck KGaA and now part of Mylan. Compelling reasons to buy this Espicom market report - Espicom is a leading provider of market...

Oncothyreon reports third quarter 2009 financial results & provides product pipeline update.
PR Newswire; 11/11/2009; 2784 words; ...our Edmonton, Alberta facility to Merck KGaA. General and administrative expenses...transfer of manufacturing of Stimuvax to Merck KGaA in December 2008. Oncothyreon reported...development activities for Stimuvax to Merck KGaA and of the previously announced plan...